Global Neuraminidase Inhibitor Market Growth 2020-2025
COVID-19, the disease it causes, surfaced in late 2019, and now had become a full-blown crisis worldwide. Over fifty key countries had declared a national emergency to combat coronavirus. With cases spreading, and the epicentre of the outbreak shifting to Europe, North America, India and Latin America, life in these regions has been upended the way it had been in Asia earlier in the developing crisis. As the coronavirus pandemic has worsened, the entertainment industry has been upended along with most every other facet of life. As experts work toward a better understanding, the world shudders in fear of the unknown, a worry that has rocked global financial markets, leading to daily volatility in the U.S. stock markets.
According to this latest study, the 2020 growth of Neuraminidase Inhibitor will have significant change from previous year. By the most conservative estimates of global Neuraminidase Inhibitor market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. We give this scenario a XX% probability, where under the scenario the supply chain will start to recover and quarantines and travel bans will ease, over the Q2. Longer-term, the effect of COVID-19 will be felt throughout the year with some degree of harm done by the virus. Over the next five years the Neuraminidase Inhibitor market will register a XX% CAGR in terms of revenue, the global market size will reach US$ XX million by 2025.
This report presents a comprehensive overview, market shares, and growth opportunities of Neuraminidase Inhibitor market by product type, application, key manufacturers and key regions and countries.
This study specially analyses the impact of Covid-19 outbreak on the Neuraminidase Inhibitor, covering the supply chain analysis, impact assessment to the Neuraminidase Inhibitor market size growth rate in several scenarios, and the measures to be undertaken by Neuraminidase Inhibitor companies in response to the COVID-19 epidemic.
Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
Zanamivir
Oseltamivir
Peramivir
Laninamivir
Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Hospital Pharmacies
Drug Stores
Retail Stores
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
GlaxoSmithKline
Gilead Sciences
BioCryst
Daiichi Sankyo
F. Hoffman-La Roche
...
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Neuraminidase Inhibitor consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Neuraminidase Inhibitor market by identifying its various subsegments.
Focuses on the key global Neuraminidase Inhibitor manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Neuraminidase Inhibitor with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Neuraminidase Inhibitor submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 What is the Impact of Covid-19 Outbreak On the Neuraminidase Inhibitor?
1.8.1 Optimistic Scenario: COVID-19 Is Contained by May or June, with Normalcy Returning to Global Operations Through the End of Q2.
1.8.2 Conservative Scenario: COVID-19 Remains Prevalent, with Continued Impacts Lasting Into Q4.
1.8.3 Estimated Impact of the Coronavirus (COVID-19) Epidemic on the Global Neuraminidase Inhibitor Market Size in 2020, by Scenario
1.8.4 Corporate Strategy the Manufacturers Should Be Thinking About Right Now
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Neuraminidase Inhibitor Consumption 2015-2025
2.1.2 Neuraminidase Inhibitor Consumption CAGR by Region
2.2 Neuraminidase Inhibitor Segment by Type
2.2.1 Zanamivir
2.2.2 Oseltamivir
2.2.3 Peramivir
2.2.4 Laninamivir
2.3 Neuraminidase Inhibitor Consumption by Type
2.3.1 Global Neuraminidase Inhibitor Consumption Market Share by Type (2015-2020)
2.3.2 Global Neuraminidase Inhibitor Revenue and Market Share by Type (2015-2020)
2.3.3 Global Neuraminidase Inhibitor Sale Price by Type (2015-2020)
2.4 Neuraminidase Inhibitor Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Drug Stores
2.4.3 Retail Stores
2.4.4 Others
2.5 Neuraminidase Inhibitor Consumption by Application
2.5.1 Global Neuraminidase Inhibitor Consumption Market Share by Type (2015-2020)
2.5.2 Global Neuraminidase Inhibitor Value and Market Share by Type (2015-2020)
2.5.3 Global Neuraminidase Inhibitor Sale Price by Type (2015-2020)
3 Global Neuraminidase Inhibitor by Company
3.1 Global Neuraminidase Inhibitor Sales Market Share by Company
3.1.1 Global Neuraminidase Inhibitor Sales by Company (2018-2020)
3.1.2 Global Neuraminidase Inhibitor Sales Market Share by Company (2018-2020)
3.2 Global Neuraminidase Inhibitor Revenue Market Share by Company
3.2.1 Global Neuraminidase Inhibitor Revenue by Company (2018-2020)
3.2.2 Global Neuraminidase Inhibitor Revenue Market Share by Company (2018-2020)
3.3 Global Neuraminidase Inhibitor Sale Price by Company
3.4 Global Neuraminidase Inhibitor Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Neuraminidase Inhibitor Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Neuraminidase Inhibitor Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 Neuraminidase Inhibitor by Regions
4.1 Neuraminidase Inhibitor by Regions
4.2 Americas Neuraminidase Inhibitor Consumption Growth
4.3 APAC Neuraminidase Inhibitor Consumption Growth
4.4 Europe Neuraminidase Inhibitor Consumption Growth
4.5 Middle East & Africa Neuraminidase Inhibitor Consumption Growth
5 Americas
5.1 Americas Neuraminidase Inhibitor Consumption by Countries
5.1.1 Americas Neuraminidase Inhibitor Consumption by Countries (2015-2020)
5.1.2 Americas Neuraminidase Inhibitor Value by Countries (2015-2020)
5.2 Americas Neuraminidase Inhibitor Consumption by Type
5.3 Americas Neuraminidase Inhibitor Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC Neuraminidase Inhibitor Consumption by Regions
6.1.1 APAC Neuraminidase Inhibitor Consumption by Regions (2015-2020)
6.1.2 APAC Neuraminidase Inhibitor Value by Regions (2015-2020)
6.2 APAC Neuraminidase Inhibitor Consumption by Type
6.3 APAC Neuraminidase Inhibitor Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions
7 Europe
7.1 Europe Neuraminidase Inhibitor by Countries
7.1.1 Europe Neuraminidase Inhibitor Consumption by Countries (2015-2020)
7.1.2 Europe Neuraminidase Inhibitor Value by Countries (2015-2020)
7.2 Europe Neuraminidase Inhibitor Consumption by Type
7.3 Europe Neuraminidase Inhibitor Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
8.1 Middle East & Africa Neuraminidase Inhibitor by Countries
8.1.1 Middle East & Africa Neuraminidase Inhibitor Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Neuraminidase Inhibitor Value by Countries (2015-2020)
8.2 Middle East & Africa Neuraminidase Inhibitor Consumption by Type
8.3 Middle East & Africa Neuraminidase Inhibitor Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Neuraminidase Inhibitor Distributors
10.3 Neuraminidase Inhibitor Customer
11 Global Neuraminidase Inhibitor Market Forecast
11.1 Global Neuraminidase Inhibitor Consumption Forecast (2021-2025)
11.2 Global Neuraminidase Inhibitor Forecast by Regions
11.2.1 Global Neuraminidase Inhibitor Forecast by Regions (2021-2025)
11.2.2 Global Neuraminidase Inhibitor Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Neuraminidase Inhibitor Forecast by Type
11.8 Global Neuraminidase Inhibitor Forecast by Application
12 Key Players Analysis
12.1 GlaxoSmithKline
12.1.1 Company Information
12.1.2 Neuraminidase Inhibitor Product Offered
12.1.3 GlaxoSmithKline Neuraminidase Inhibitor Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 GlaxoSmithKline Latest Developments
12.2 Gilead Sciences
12.2.1 Company Information
12.2.2 Neuraminidase Inhibitor Product Offered
12.2.3 Gilead Sciences Neuraminidase Inhibitor Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 Gilead Sciences Latest Developments
12.3 BioCryst
12.3.1 Company Information
12.3.2 Neuraminidase Inhibitor Product Offered
12.3.3 BioCryst Neuraminidase Inhibitor Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 BioCryst Latest Developments
12.4 Daiichi Sankyo
12.4.1 Company Information
12.4.2 Neuraminidase Inhibitor Product Offered
12.4.3 Daiichi Sankyo Neuraminidase Inhibitor Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 Daiichi Sankyo Latest Developments
12.5 F. Hoffman-La Roche
12.5.1 Company Information
12.5.2 Neuraminidase Inhibitor Product Offered
12.5.3 F. Hoffman-La Roche Neuraminidase Inhibitor Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 F. Hoffman-La Roche Latest Developments
...
13 Research Findings and Conclusion
List of Tables
Table 1. Estimated Impact of the Coronavirus (COVID-19) Epidemic on the Global Neuraminidase Inhibitor Market Size in 2020, by Scenario
Table 2. COVID-19: Measures to be Undertaken by Neuraminidase Inhibitor Companies
Table 3. Research Methodology
Table 4. Data Source
Table 5. Neuraminidase Inhibitor Consumption CAGR by Region 2015-2025 ($ Millions)
Table 6. Major Players of Zanamivir
Table 7. Major Players of Oseltamivir
Table 8. Major Players of Peramivir
Table 9. Major Players of Laninamivir
Table 10. Global Consumption Sales by Type (2015-2020)
Table 11. Global Neuraminidase Inhibitor Consumption Market Share by Type (2015-2020)
Table 12. Global Neuraminidase Inhibitor Revenue by Type (2015-2020) ($ million)
Table 13. Global Neuraminidase Inhibitor Value Market Share by Type (2015-2020) ($ Millions)
Table 14. Global Neuraminidase Inhibitor Sale Price by Type (2015-2020)
Table 15. Global Consumption Sales by Application (2015-2020)
Table 16. Global Neuraminidase Inhibitor Consumption Market Share by Application (2015-2020)
Table 17. Global Neuraminidase Inhibitor Value by Application (2015-2020)
Table 18. Global Neuraminidase Inhibitor Value Market Share by Application (2015-2020)
Table 19. Global Neuraminidase Inhibitor Sale Price by Application (2015-2020)
Table 20. Global Neuraminidase Inhibitor Sales by Company (2017-2019) (K Units)
Table 21. Global Neuraminidase Inhibitor Sales Market Share by Company (2017-2019)
Table 22. Global Neuraminidase Inhibitor Revenue by Company (2017-2019) ($ Millions)
Table 23. Global Neuraminidase Inhibitor Revenue Market Share by Company (2017-2019)
Table 24. Global Neuraminidase Inhibitor Sale Price by Company (2017-2019)
Table 25. Global Neuraminidase Inhibitor Manufacturing Base Distribution and Sales Area by Manufacturers
Table 26. Players Neuraminidase Inhibitor Products Offered
Table 27. Neuraminidase Inhibitor Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
Table 28. Global Neuraminidase Inhibitor Consumption by Regions 2015-2020 (K Units)
Table 29. Global Neuraminidase Inhibitor Consumption Market Share by Regions 2015-2020
Table 30. Global Neuraminidase Inhibitor Value by Regions 2015-2020 ($ Millions)
Table 31. Global Neuraminidase Inhibitor Value Market Share by Regions 2015-2020
Table 32. Americas Neuraminidase Inhibitor Consumption by Countries (2015-2020) (K Units)
Table 33. Americas Neuraminidase Inhibitor Consumption Market Share by Countries (2015-2020)
Table 34. Americas Neuraminidase Inhibitor Value by Countries (2015-2020) ($ Millions)
Table 35. Americas Neuraminidase Inhibitor Value Market Share by Countries (2015-2020)
Table 36. Americas Neuraminidase Inhibitor Consumption by Type (2015-2020) (K Units)
Table 37. Americas Neuraminidase Inhibitor Consumption Market Share by Type (2015-2020)
Table 38. Americas Neuraminidase Inhibitor Consumption by Application (2015-2020) (K Units)
Table 39. Americas Neuraminidase Inhibitor Consumption Market Share by Application (2015-2020)
Table 40. APAC Neuraminidase Inhibitor Consumption by Countries (2015-2020) (K Units)
Table 41. APAC Neuraminidase Inhibitor Consumption Market Share by Countries (2015-2020)
Table 42. APAC Neuraminidase Inhibitor Value by Regions (2015-2020) ($ Millions)
Table 43. APAC Neuraminidase Inhibitor Value Market Share by Regions (2015-2020)
Table 44. APAC Neuraminidase Inhibitor Consumption by Type (2015-2020) (K Units)
Table 45. APAC Neuraminidase Inhibitor Consumption Market Share by Type (2015-2020)
Table 46. APAC Neuraminidase Inhibitor Consumption by Application (2015-2020) (K Units)
Table 47. APAC Neuraminidase Inhibitor Consumption Market Share by Application (2015-2020)
Table 48. Europe Neuraminidase Inhibitor Consumption by Countries (2015-2020) (K Units)
Table 49. Europe Neuraminidase Inhibitor Consumption Market Share by Countries (2015-2020)
Table 50. Europe Neuraminidase Inhibitor Value by Countries (2015-2020) ($ Millions)
Table 51. Europe Neuraminidase Inhibitor Value Market Share by Countries (2015-2020)
Table 52. Europe Neuraminidase Inhibitor Consumption by Type (2015-2020) (K Units)
Table 53. Europe Neuraminidase Inhibitor Consumption Market Share by Type (2015-2020)
Table 54. Europe Neuraminidase Inhibitor Consumption by Application (2015-2020) (K Units)
Table 55. Europe Neuraminidase Inhibitor Consumption Market Share by Application (2015-2020)
Table 56. Middle East & Africa Neuraminidase Inhibitor Consumption by Countries (2015-2020) (K Units)
Table 57. Middle East & Africa Neuraminidase Inhibitor Consumption Market Share by Countries (2015-2020)
Table 58. Middle East & Africa Neuraminidase Inhibitor Value by Countries (2015-2020) ($ Millions)
Table 59. Middle East & Africa Neuraminidase Inhibitor Value Market Share by Countries (2015-2020)
Table 60. Middle East & Africa Neuraminidase Inhibitor Consumption by Type (2015-2020) (K Units)
Table 61. Middle East & Africa Neuraminidase Inhibitor Consumption Market Share by Type (2015-2020)
Table 62. Middle East & Africa Neuraminidase Inhibitor Consumption by Application (2015-2020) (K Units)
Table 63. Middle East & Africa Neuraminidase Inhibitor Consumption Market Share by Application (2015-2020)
Table 64. Neuraminidase Inhibitor Distributors List
Table 65. Neuraminidase Inhibitor Customer List
Table 66. Global Neuraminidase Inhibitor Consumption Forecast by Countries (2021-2025) (K Units)
Table 67. Global Neuraminidase Inhibitor Consumption Market Forecast by Regions
Table 68. Global Neuraminidase Inhibitor Value Forecast by Countries (2021-2025) ($ Millions)
Table 69. Global Neuraminidase Inhibitor Value Market Share Forecast by Regions
Table 70. Global Neuraminidase Inhibitor Consumption Forecast by Type (2021-2025) (K Units)
Table 71. Global Neuraminidase Inhibitor Consumption Market Share Forecast by Type (2021-2025)
Table 72. Global Neuraminidase Inhibitor Value Forecast by Type (2021-2025) ($ Millions)
Table 73. Global Neuraminidase Inhibitor Value Market Share Forecast by Type (2021-2025)
Table 74. Global Neuraminidase Inhibitor Consumption Forecast by Application (2021-2025) (K Units)
Table 75. Global Neuraminidase Inhibitor Consumption Market Share Forecast by Application (2021-2025)
Table 76. Global Neuraminidase Inhibitor Value Forecast by Application (2021-2025) ($ Millions)
Table 77. Global Neuraminidase Inhibitor Value Market Share Forecast by Application (2021-2025)
Table 78. GlaxoSmithKline Product Offered
Table 79. GlaxoSmithKline Neuraminidase Inhibitor Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 80. GlaxoSmithKline Main Business
Table 81. GlaxoSmithKline Latest Developments
Table 82. GlaxoSmithKline Basic Information, Company Total Revenue (in $ million), Neuraminidase Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 83. Gilead Sciences Product Offered
Table 84. Gilead Sciences Neuraminidase Inhibitor Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 85. Gilead Sciences Main Business
Table 86. Gilead Sciences Latest Developments
Table 87. Gilead Sciences Basic Information, Company Total Revenue (in $ million), Neuraminidase Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 88. BioCryst Product Offered
Table 89. BioCryst Neuraminidase Inhibitor Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 90. BioCryst Main Business
Table 91. BioCryst Latest Developments
Table 92. BioCryst Basic Information, Company Total Revenue (in $ million), Neuraminidase Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 93. Daiichi Sankyo Product Offered
Table 94. Daiichi Sankyo Neuraminidase Inhibitor Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 95. Daiichi Sankyo Main Business
Table 96. Daiichi Sankyo Latest Developments
Table 97. Daiichi Sankyo Basic Information, Company Total Revenue (in $ million), Neuraminidase Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 98. F. Hoffman-La Roche Product Offered
Table 99. F. Hoffman-La Roche Neuraminidase Inhibitor Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 100. F. Hoffman-La Roche Main Business
Table 101. F. Hoffman-La Roche Latest Developments
Table 102. F. Hoffman-La Roche Basic Information, Company Total Revenue (in $ million), Neuraminidase Inhibitor Manufacturing Base, Sales Area and Its Competitors
List of Figures
Figure 1. Picture of Neuraminidase Inhibitor
Figure 2. Neuraminidase Inhibitor Report Years Considered
Figure 3. Market Research Methodology
Figure 4. Global Neuraminidase Inhibitor Consumption Growth Rate 2015-2025 (K Units)
Figure 5. Global Neuraminidase Inhibitor Value Growth Rate 2015-2025 ($ Millions)
Figure 6. Product Picture of Zanamivir
Figure 7. Product Picture of Oseltamivir
Figure 8. Product Picture of Peramivir
Figure 9. Product Picture of Laninamivir
Figure 10. Global Neuraminidase Inhibitor Consumption Market Share by Type (2015-2020)
Figure 11. Global Neuraminidase Inhibitor Value Market Share by Type (2015-2020)
Figure 12. Neuraminidase Inhibitor Consumed in Hospital Pharmacies
Figure 13. Global Neuraminidase Inhibitor Market: Hospital Pharmacies (2015-2020) (K Units)
Figure 14. Global Neuraminidase Inhibitor Market: Hospital Pharmacies (2015-2020) ($ Millions)
Figure 15. Neuraminidase Inhibitor Consumed in Drug Stores
Figure 16. Global Neuraminidase Inhibitor Market: Drug Stores (2015-2020) (K Units)
Figure 17. Global Neuraminidase Inhibitor Market: Drug Stores (2015-2020) ($ Millions)
Figure 18. Neuraminidase Inhibitor Consumed in Retail Stores
Figure 19. Global Neuraminidase Inhibitor Market: Retail Stores (2015-2020) (K Units)
Figure 20. Global Neuraminidase Inhibitor Market: Retail Stores (2015-2020) ($ Millions)
Figure 21. Neuraminidase Inhibitor Consumed in Others
Figure 22. Global Neuraminidase Inhibitor Market: Others (2015-2020) (K Units)
Figure 23. Global Neuraminidase Inhibitor Market: Others (2015-2020) ($ Millions)
Figure 24. Global Neuraminidase Inhibitor Consumption Market Share by Application (2015-2020)
Figure 25. Global Neuraminidase Inhibitor Value Market Share by Application (2015-2020)
Figure 26. Global Neuraminidase Inhibitor Sales Market Share by Company in 2017
Figure 27. Global Neuraminidase Inhibitor Sales Market Share by Company in 2019
Figure 28. Global Neuraminidase Inhibitor Revenue Market Share by Company in 2017
Figure 29. Global Neuraminidase Inhibitor Revenue Market Share by Company in 2019
Figure 30. Global Neuraminidase Inhibitor Sale Price by Company in 2019
Figure 31. Global Neuraminidase Inhibitor Consumption Market Share by Regions 2015-2020
Figure 32. Global Neuraminidase Inhibitor Value Market Share by Regions 2015-2020
Figure 33. Americas Neuraminidase Inhibitor Consumption 2015-2020 (K Units)
Figure 34. Americas Neuraminidase Inhibitor Value 2015-2020 ($ Millions)
Figure 35. APAC Neuraminidase Inhibitor Consumption 2015-2020 (K Units)
Figure 36. APAC Neuraminidase Inhibitor Value 2015-2020 ($ Millions)
Figure 37. Europe Neuraminidase Inhibitor Consumption 2015-2020 (K Units)
Figure 38. Europe Neuraminidase Inhibitor Value 2015-2020 ($ Millions)
Figure 39. Middle East & Africa Neuraminidase Inhibitor Consumption 2015-2020 (K Units)
Figure 40. Middle East & Africa Neuraminidase Inhibitor Value 2015-2020 ($ Millions)
Figure 41. Americas Neuraminidase Inhibitor Consumption Market Share by Countries in 2019
Figure 42. Americas Neuraminidase Inhibitor Value Market Share by Countries in 2019
Figure 43. Americas Neuraminidase Inhibitor Consumption Market Share by Type in 2019
Figure 44. Americas Neuraminidase Inhibitor Consumption Market Share by Application in 2019
Figure 45. United States Neuraminidase Inhibitor Consumption Growth 2015-2020 (K Units)
Figure 46. United States Neuraminidase Inhibitor Value Growth 2015-2020 ($ Millions)
Figure 47. Canada Neuraminidase Inhibitor Consumption Growth 2015-2020 (K Units)
Figure 48. Canada Neuraminidase Inhibitor Value Growth 2015-2020 ($ Millions)
Figure 49. Mexico Neuraminidase Inhibitor Consumption Growth 2015-2020 (K Units)
Figure 50. Mexico Neuraminidase Inhibitor Value Growth 2015-2020 ($ Millions)
Figure 51. APAC Neuraminidase Inhibitor Consumption Market Share by Countries in 2019
Figure 52. APAC Neuraminidase Inhibitor Value Market Share by Regions in 2019
Figure 53. APAC Neuraminidase Inhibitor Consumption Market Share by Type in 2019
Figure 54. APAC Neuraminidase Inhibitor Consumption Market Share by Application in 2019
Figure 55. China Neuraminidase Inhibitor Consumption Growth 2015-2020 (K Units)
Figure 56. China Neuraminidase Inhibitor Value Growth 2015-2020 ($ Millions)
Figure 57. Japan Neuraminidase Inhibitor Consumption Growth 2015-2020 (K Units)
Figure 58. Japan Neuraminidase Inhibitor Value Growth 2015-2020 ($ Millions)
Figure 59. Korea Neuraminidase Inhibitor Consumption Growth 2015-2020 (K Units)
Figure 60. Korea Neuraminidase Inhibitor Value Growth 2015-2020 ($ Millions)
Figure 61. Southeast Asia Neuraminidase Inhibitor Consumption Growth 2015-2020 (K Units)
Figure 62. Southeast Asia Neuraminidase Inhibitor Value Growth 2015-2020 ($ Millions)
Figure 63. India Neuraminidase Inhibitor Consumption Growth 2015-2020 (K Units)
Figure 64. India Neuraminidase Inhibitor Value Growth 2015-2020 ($ Millions)
Figure 65. Australia Neuraminidase Inhibitor Consumption Growth 2015-2020 (K Units)
Figure 66. Australia Neuraminidase Inhibitor Value Growth 2015-2020 ($ Millions)
Figure 67. Europe Neuraminidase Inhibitor Consumption Market Share by Countries in 2019
Figure 68. Europe Neuraminidase Inhibitor Value Market Share by Countries in 2019
Figure 69. Europe Neuraminidase Inhibitor Consumption Market Share by Type in 2019
Figure 70. Europe Neuraminidase Inhibitor Consumption Market Share by Application in 2019
Figure 71. Germany Neuraminidase Inhibitor Consumption Growth 2015-2020 (K Units)
Figure 72. Germany Neuraminidase Inhibitor Value Growth 2015-2020 ($ Millions)
Figure 73. France Neuraminidase Inhibitor Consumption Growth 2015-2020 (K Units)
Figure 74. France Neuraminidase Inhibitor Value Growth 2015-2020 ($ Millions)
Figure 75. UK Neuraminidase Inhibitor Consumption Growth 2015-2020 (K Units)
Figure 76. UK Neuraminidase Inhibitor Value Growth 2015-2020 ($ Millions)
Figure 77. Italy Neuraminidase Inhibitor Consumption Growth 2015-2020 (K Units)
Figure 78. Italy Neuraminidase Inhibitor Value Growth 2015-2020 ($ Millions)
Figure 79. Russia Neuraminidase Inhibitor Consumption Growth 2015-2020 (K Units)
Figure 80. Russia Neuraminidase Inhibitor Value Growth 2015-2020 ($ Millions)
Figure 81. Middle East & Africa Neuraminidase Inhibitor Consumption Market Share by Countries in 2019
Figure 82. Middle East & Africa Neuraminidase Inhibitor Value Market Share by Countries in 2019
Figure 83. Middle East & Africa Neuraminidase Inhibitor Consumption Market Share by Type in 2019
Figure 84. Middle East & Africa Neuraminidase Inhibitor Consumption Market Share by Application in 2019
Figure 85. Egypt Neuraminidase Inhibitor Consumption Growth 2015-2020 (K Units)
Figure 86. Egypt Neuraminidase Inhibitor Value Growth 2015-2020 ($ Millions)
Figure 87. South Africa Neuraminidase Inhibitor Consumption Growth 2015-2020 (K Units)
Figure 88. South Africa Neuraminidase Inhibitor Value Growth 2015-2020 ($ Millions)
Figure 89. Israel Neuraminidase Inhibitor Consumption Growth 2015-2020 (K Units)
Figure 90. Israel Neuraminidase Inhibitor Value Growth 2015-2020 ($ Millions)
Figure 91. Turkey Neuraminidase Inhibitor Consumption Growth 2015-2020 (K Units)
Figure 92. Turkey Neuraminidase Inhibitor Value Growth 2015-2020 ($ Millions)
Figure 93. GCC Countries Neuraminidase Inhibitor Consumption Growth 2015-2020 (K Units)
Figure 94. GCC Countries Neuraminidase Inhibitor Value Growth 2015-2020 ($ Millions)
Figure 95. Global Neuraminidase Inhibitor Consumption Growth Rate Forecast (2021-2025) (K Units)
Figure 96. Global Neuraminidase Inhibitor Value Growth Rate Forecast (2021-2025) ($ Millions)
Figure 97. Americas Neuraminidase Inhibitor Consumption 2021-2025 (K Units)
Figure 98. Americas Neuraminidase Inhibitor Value 2021-2025 ($ Millions)
Figure 99. APAC Neuraminidase Inhibitor Consumption 2021-2025 (K Units)
Figure 100. APAC Neuraminidase Inhibitor Value 2021-2025 ($ Millions)
Figure 101. Europe Neuraminidase Inhibitor Consumption 2021-2025 (K Units)
Figure 102. Europe Neuraminidase Inhibitor Value 2021-2025 ($ Millions)
Figure 103. Middle East & Africa Neuraminidase Inhibitor Consumption 2021-2025 (K Units)
Figure 104. Middle East & Africa Neuraminidase Inhibitor Value 2021-2025 ($ Millions)
Figure 105. United States Neuraminidase Inhibitor Consumption 2021-2025 (K Units)
Figure 106. United States Neuraminidase Inhibitor Value 2021-2025 ($ Millions)
Figure 107. Canada Neuraminidase Inhibitor Consumption 2021-2025 (K Units)
Figure 108. Canada Neuraminidase Inhibitor Value 2021-2025 ($ Millions)
Figure 109. Mexico Neuraminidase Inhibitor Consumption 2021-2025 (K Units)
Figure 110. Mexico Neuraminidase Inhibitor Value 2021-2025 ($ Millions)
Figure 111. Brazil Neuraminidase Inhibitor Consumption 2021-2025 (K Units)
Figure 112. Brazil Neuraminidase Inhibitor Value 2021-2025 ($ Millions)
Figure 113. China Neuraminidase Inhibitor Consumption 2021-2025 (K Units)
Figure 114. China Neuraminidase Inhibitor Value 2021-2025 ($ Millions)
Figure 115. Japan Neuraminidase Inhibitor Consumption 2021-2025 (K Units)
Figure 116. Japan Neuraminidase Inhibitor Value 2021-2025 ($ Millions)
Figure 117. Korea Neuraminidase Inhibitor Consumption 2021-2025 (K Units)
Figure 118. Korea Neuraminidase Inhibitor Value 2021-2025 ($ Millions)
Figure 119. Southeast Asia Neuraminidase Inhibitor Consumption 2021-2025 (K Units)
Figure 120. Southeast Asia Neuraminidase Inhibitor Value 2021-2025 ($ Millions)
Figure 121. India Neuraminidase Inhibitor Consumption 2021-2025 (K Units)
Figure 122. India Neuraminidase Inhibitor Value 2021-2025 ($ Millions)
Figure 123. Australia Neuraminidase Inhibitor Consumption 2021-2025 (K Units)
Figure 124. Australia Neuraminidase Inhibitor Value 2021-2025 ($ Millions)
Figure 125. Germany Neuraminidase Inhibitor Consumption 2021-2025 (K Units)
Figure 126. Germany Neuraminidase Inhibitor Value 2021-2025 ($ Millions)
Figure 127. France Neuraminidase Inhibitor Consumption 2021-2025 (K Units)
Figure 128. France Neuraminidase Inhibitor Value 2021-2025 ($ Millions)
Figure 129. UK Neuraminidase Inhibitor Consumption 2021-2025 (K Units)
Figure 130. UK Neuraminidase Inhibitor Value 2021-2025 ($ Millions)
Figure 131. Italy Neuraminidase Inhibitor Consumption 2021-2025 (K Units)
Figure 132. Italy Neuraminidase Inhibitor Value 2021-2025 ($ Millions)
Figure 133. Russia Neuraminidase Inhibitor Consumption 2021-2025 (K Units)
Figure 134. Russia Neuraminidase Inhibitor Value 2021-2025 ($ Millions)
Figure 135. Spain Neuraminidase Inhibitor Consumption 2021-2025 (K Units)
Figure 136. Spain Neuraminidase Inhibitor Value 2021-2025 ($ Millions)
Figure 137. Egypt Neuraminidase Inhibitor Consumption 2021-2025 (K Units)
Figure 138. Egypt Neuraminidase Inhibitor Value 2021-2025 ($ Millions)
Figure 139. South Africa Neuraminidase Inhibitor Consumption 2021-2025 (K Units)
Figure 140. South Africa Neuraminidase Inhibitor Value 2021-2025 ($ Millions)
Figure 141. Israel Neuraminidase Inhibitor Consumption 2021-2025 (K Units)
Figure 142. Israel Neuraminidase Inhibitor Value 2021-2025 ($ Millions)
Figure 143. Turkey Neuraminidase Inhibitor Consumption 2021-2025 (K Units)
Figure 144. Turkey Neuraminidase Inhibitor Value 2021-2025 ($ Millions)
Figure 145. GCC Countries Neuraminidase Inhibitor Consumption 2021-2025 (K Units)
Figure 146. GCC Countries Neuraminidase Inhibitor Value 2021-2025 ($ Millions)
Figure 147. GlaxoSmithKline Neuraminidase Inhibitor Market Share (2018-2020)
Figure 148. Gilead Sciences Neuraminidase Inhibitor Market Share (2018-2020)
Figure 149. BioCryst Neuraminidase Inhibitor Market Share (2018-2020)
Figure 150. Daiichi Sankyo Neuraminidase Inhibitor Market Share (2018-2020)
Figure 151. F. Hoffman-La Roche Neuraminidase Inhibitor Market Share (2018-2020)
